Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

Prior treatment

• Receipt of any investigational drug within 3 months before study inclusion
• Concomitant treatment with a biological disease-modifying antirheumatic drugs (bDMARD)

Other illness

• Recent herpes zoster infection (within past 6 months) or history of severe disseminated herpes zoster infection
• Active treatment for a malignancy

Other

• Contraindications according to the Xeljanz® (tofacitinib) Prescribing Information
• Patient is pregnant or breastfeeding

• Patients aged ≥ 18 years
• Moderate to severe PsA disease activity diagnosed
• Patients for whom the physician's decision has been made to initiate treatment with tofacitinib, in usual clinical practice conditions and in compliance with the local label
• Patients are treatment naïve to tofacitinib on the date of providing informed consent
• Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
• Patients on DMARDs must have not had a treatment change in the past 3 months